|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FGF1 |
Gene summary for FGF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FGF1 | Gene ID | 2246 |
| Gene name | fibroblast growth factor 1 | |
| Gene Alias | AFGF | |
| Cytomap | 5q31.3 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P05230 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2246 | FGF1 | C30 | Human | Oral cavity | OSCC | 4.88e-15 | 8.37e-01 | 0.3055 |
| 2246 | FGF1 | C38 | Human | Oral cavity | OSCC | 1.95e-05 | 5.08e-01 | 0.172 |
| 2246 | FGF1 | C43 | Human | Oral cavity | OSCC | 1.19e-10 | 1.90e-01 | 0.1704 |
| 2246 | FGF1 | ATC2 | Human | Thyroid | ATC | 9.20e-14 | 1.53e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00109776 | Prostate | BPH | negative regulation of neuron projection development | 36/3107 | 137/18723 | 2.64e-03 | 1.41e-02 | 36 |
| GO:00083617 | Prostate | BPH | regulation of cell size | 45/3107 | 181/18723 | 2.79e-03 | 1.47e-02 | 45 |
| GO:19031156 | Prostate | BPH | regulation of actin filament-based movement | 14/3107 | 39/18723 | 2.81e-03 | 1.48e-02 | 14 |
| GO:00486388 | Prostate | BPH | regulation of developmental growth | 74/3107 | 330/18723 | 3.43e-03 | 1.76e-02 | 74 |
| GO:00507706 | Prostate | BPH | regulation of axonogenesis | 39/3107 | 154/18723 | 3.65e-03 | 1.85e-02 | 39 |
| GO:00311102 | Prostate | BPH | regulation of microtubule polymerization or depolymerization | 25/3107 | 88/18723 | 3.76e-03 | 1.89e-02 | 25 |
| GO:0007611 | Prostate | BPH | learning or memory | 59/3107 | 255/18723 | 4.12e-03 | 2.04e-02 | 59 |
| GO:000202810 | Prostate | BPH | regulation of sodium ion transport | 25/3107 | 90/18723 | 5.18e-03 | 2.43e-02 | 25 |
| GO:190230514 | Prostate | BPH | regulation of sodium ion transmembrane transport | 20/3107 | 68/18723 | 5.92e-03 | 2.73e-02 | 20 |
| GO:00436243 | Prostate | BPH | cellular protein complex disassembly | 34/3107 | 136/18723 | 7.81e-03 | 3.42e-02 | 34 |
| GO:00512614 | Prostate | BPH | protein depolymerization | 29/3107 | 114/18723 | 1.04e-02 | 4.35e-02 | 29 |
| GO:00860018 | Prostate | BPH | cardiac muscle cell action potential | 21/3107 | 76/18723 | 1.05e-02 | 4.39e-02 | 21 |
| GO:19018802 | Prostate | BPH | negative regulation of protein depolymerization | 20/3107 | 72/18723 | 1.16e-02 | 4.70e-02 | 20 |
| GO:00309004 | Prostate | BPH | forebrain development | 80/3107 | 379/18723 | 1.19e-02 | 4.82e-02 | 80 |
| GO:00551176 | Prostate | BPH | regulation of cardiac muscle contraction | 21/3107 | 77/18723 | 1.22e-02 | 4.93e-02 | 21 |
| GO:190290319 | Prostate | Tumor | regulation of supramolecular fiber organization | 131/3246 | 383/18723 | 6.68e-16 | 1.26e-13 | 131 |
| GO:003297019 | Prostate | Tumor | regulation of actin filament-based process | 133/3246 | 397/18723 | 2.59e-15 | 4.35e-13 | 133 |
| GO:001604916 | Prostate | Tumor | cell growth | 137/3246 | 482/18723 | 7.01e-10 | 3.51e-08 | 137 |
| GO:000716317 | Prostate | Tumor | establishment or maintenance of cell polarity | 74/3246 | 218/18723 | 2.00e-09 | 8.86e-08 | 74 |
| GO:007265917 | Prostate | Tumor | protein localization to plasma membrane | 90/3246 | 284/18723 | 2.07e-09 | 8.99e-08 | 90 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0401014 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
| hsa0481026 | Oral cavity | OSCC | Regulation of actin cytoskeleton | 129/3704 | 229/8465 | 7.14e-05 | 2.74e-04 | 1.40e-04 | 129 |
| hsa041516 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
| hsa0439016 | Oral cavity | OSCC | Hippo signaling pathway | 86/3704 | 157/8465 | 3.30e-03 | 8.24e-03 | 4.20e-03 | 86 |
| hsa0401518 | Oral cavity | OSCC | Rap1 signaling pathway | 107/3704 | 210/8465 | 2.01e-02 | 4.34e-02 | 2.21e-02 | 107 |
| hsa0401015 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
| hsa04810111 | Oral cavity | OSCC | Regulation of actin cytoskeleton | 129/3704 | 229/8465 | 7.14e-05 | 2.74e-04 | 1.40e-04 | 129 |
| hsa0415113 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
| hsa0439017 | Oral cavity | OSCC | Hippo signaling pathway | 86/3704 | 157/8465 | 3.30e-03 | 8.24e-03 | 4.20e-03 | 86 |
| hsa0401519 | Oral cavity | OSCC | Rap1 signaling pathway | 107/3704 | 210/8465 | 2.01e-02 | 4.34e-02 | 2.21e-02 | 107 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| FGF1 | FGFR1 | FGF1_FGFR1 | FGF | Cervix | CC |
| FGF1 | FGFR2 | FGF1_FGFR2 | FGF | Cervix | CC |
| FGF1 | FGFR3 | FGF1_FGFR3 | FGF | Cervix | CC |
| FGF1 | FGFR1 | FGF1_FGFR1 | FGF | Esophagus | ESCC |
| FGF1 | FGFR3 | FGF1_FGFR3 | FGF | Esophagus | ESCC |
| FGF1 | FGFR4 | FGF1_FGFR4 | FGF | Esophagus | ESCC |
| FGF1 | FGFR1 | FGF1_FGFR1 | FGF | HNSCC | OSCC |
| FGF1 | FGFR2 | FGF1_FGFR2 | FGF | HNSCC | OSCC |
| FGF1 | FGFR3 | FGF1_FGFR3 | FGF | HNSCC | OSCC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FGF1 | SNV | Missense_Mutation | novel | c.4N>T | p.Ala2Ser | p.A2S | P05230 | protein_coding | tolerated(0.25) | benign(0.026) | TCGA-C8-A26X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| FGF1 | SNV | Missense_Mutation | novel | c.4N>T | p.Ala2Ser | p.A2S | P05230 | protein_coding | tolerated(0.25) | benign(0.026) | TCGA-E9-A247-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| FGF1 | insertion | Frame_Shift_Ins | novel | c.53_54insTCCTGGCA | p.Pro20GlyfsTer22 | p.P20Gfs*22 | P05230 | protein_coding | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| FGF1 | SNV | Missense_Mutation | rs758967005 | c.106N>T | p.His36Tyr | p.H36Y | P05230 | protein_coding | tolerated(1) | benign(0.005) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| FGF1 | SNV | Missense_Mutation | novel | c.288G>T | p.Glu96Asp | p.E96D | P05230 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-3850-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| FGF1 | SNV | Missense_Mutation | c.298N>C | p.Phe100Leu | p.F100L | P05230 | protein_coding | deleterious(0) | possibly_damaging(0.535) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| FGF1 | SNV | Missense_Mutation | c.104N>A | p.Gly35Asp | p.G35D | P05230 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| FGF1 | SNV | Missense_Mutation | c.329N>C | p.Asn110Thr | p.N110T | P05230 | protein_coding | deleterious(0.03) | possibly_damaging(0.879) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| FGF1 | SNV | Missense_Mutation | rs773671222 | c.204N>T | p.Glu68Asp | p.E68D | P05230 | protein_coding | deleterious(0.01) | benign(0.09) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
| FGF1 | SNV | Missense_Mutation | novel | c.61N>T | p.Gly21Trp | p.G21W | P05230 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2246 | FGF1 | CLINICALLY ACTIONABLE, GROWTH FACTOR, DRUGGABLE GENOME | PENTOSAN POLYSULFATE | |||
| 2246 | FGF1 | CLINICALLY ACTIONABLE, GROWTH FACTOR, DRUGGABLE GENOME | PENTOSAN POLYSULFATE | |||
| 2246 | FGF1 | CLINICALLY ACTIONABLE, GROWTH FACTOR, DRUGGABLE GENOME | CVBT-141H | |||
| 2246 | FGF1 | CLINICALLY ACTIONABLE, GROWTH FACTOR, DRUGGABLE GENOME | inhibitor | CHEMBL1615835 | MUPARFOSTAT |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |